Dean Ho, Ph.D. (Director, Project NDX)
Dr. Ho received his Ph.D. from UCLA in Biomedical Engineering in 2005, and began his academic career in 2006 as an Assistant Professor of Biomedical Engineering and Mechanical Engineering at Northwestern University. He was promoted to Associate Professor with Tenure in 2010. He joined the UCLA faculty in 2012 as a Professor of Bioengineering, and Oral Biology and Medicine at UCLA. He is also the Co-Director of the Jane and Jerry Weintraub Center for Reconstructive Biotechnology.
Dr. Ho pioneered the development of nanodiamond-based drug delivery and leads one of the pre-eminent teams in the world in the field. Recently, Dr. Ho initiated a landmark clinical trial to validate a nanodiamond-based biomaterial to enhance root canal therapy (NCT02698163). A progress report of this trial was recently published in the Proceedings of the National Academy of Sciences and highlighted in the NIH Director's blog.
Dr. Ho has also led multiple clinical trials in the area of Augmented Artificial Intelligence (AI) for personalized and precision medicine and indications ranging from oncology to transplant immunosuppression. His team has also developed mobile/digital health technologies to optimize clinical combination therapy.
Dr. Ho's technical achievements have been featured on CNN, The Economist, Washington Post, Forbes, Chicago Tribune, and hundreds of international news outlets. He was recently the President of the Board of Directors of the Society for Laboratory Automation and Screening (SLAS), a 26,000+ member organization at the interface of the pharmaceutical and medical technology industries and academia focused on drug development, screening, and diagnostics. He is a recipient of the V Foundation for Cancer Research Scholar Award (Phase I and II), NSF CAREER Award, and Wallace H. Coulter Foundation Translational Research Award, and was named the Distinguished Young Alumnus of the UCLA School of Engineering and Applied Science, among others. He is a Fellow of the American Institute of Medical and Biological Engineering (AIMBE), which recognizes the top 2% of bioengineers in the field, and the Society for Laboratory Automation (SLAS). Dr. Ho was recently named a Fulbright Scholar.
Edward Chow, Ph.D. (Director, Cancer Biology)
Dr. Chow received his Ph.D. at UCLA in Microbiology, Immunology, and Molecular Genetics and his was an American Cancer Society postdoctoral fellow at the G.W. Hooper Medical Research Foundation/UCSF under the mentorship of Prof. J. Michael Bishop (Nobel Laureate in Medicine or Physiology). He is currently a Principal Investigator at the Cancer Science Institute of Singapore and Assistant Professor of Pharmacology at the National University of Singapore (NUS). Dr. Chow's research achievements involve the development of novel nanocarbon-based drug delivery and imaging vehicles for cancer stem cell tracking and therapeutics. He also maintains a major research program in cancer biology and bioengineering. His work has been featured in a number of major news outlets including the Chicago Tribune, NPR, and Science and Nature News. Prior to his career at NUS, Dr. Chow worked for Berlex and Genentech.
Ali Zarrinpar, M.D., Ph.D. (Director, Clinical Affairs)
Dr. Zarrinpar received his M.D. and Ph.D. degrees at the University of California, San Francisco. He completed his residency in General Surgery and Fellowship in Transplantation and Hepatobiliary Surgery at UCLA. He is currently an Assistant Professor in the Department of Surgery, Division of Liver and Pancreas Transplantation, and the Dumont-UCLA Liver Transplant and Cancer Center. He is also a member of the Jonsson Comprehensive Cancer Center. He has led numerous clinical trials pertaining to liver transplantation as well as the assessment of novel therapies for patients with liver disease and liver cancer. Dr. Zarrinpar is currently the Director of the Liver Transplant Ischemia/Reperfusion Tissue and Blood Repository and Liver Tissue Bank.
Eiji Osawa, Ph.D. (Director, Chemistry and Materials Science)
Dr. Osawa is an internationally-renowned chemist and pioneer in the nanocarbon field. He is widely recognized as among the first to theoretically predict the structure of C60. He has made major contributions towards the understanding of nanodiamond synthesis, structure, surface chemistry, and processing techniques, all of which have played a key role towards their applications in energy, diagnostics, therapeutics, and other areas. He was previously a Professor at Toyohashi University and is currently the President of the Nanocarbon Research Institute at Shinshu University. He is a recipient of the Chunichi Culture Prize. In addition, The Osawa Prize was established in honor of his seminal contributions to the nanocarbon field.
Current Team Members
Dr. Dong-Keun Lee, UCLA
Theodore Kee, UCLA
Desiree Hsiou, UCLA
Darron Miya, UCLA
Michael Trieu, UCLA
Brian Wu, UCLA
Peter Wang, UCLA
Dr. Laura Moore, Northwestern and UCSF
Masturah Bte Mohd Abdul Rashid, NUS
Nurrul Lissa Binti Abdullah, NUS
Tan Boon Toh, NUS
Xin Wang, NUS
Dr. Houjin Huang
Dr. Erik Pierstorff
Dr. Xue-Qing Zhang
Dr. Robert Lam
Dr. Sue Vin Kim
Dr. A. Nerisa Limansubroto
Prof. Ho-Joong Kim
Dr. Kangyi Zhang
...and countless other team members that made this journey possible.
Cancer Science Institute of Singapore
National University Health System
National University Cancer Institute
The V Foundation for Cancer Research
National Cancer Institute
National Science Foundation
American Chemical Society
Wallace H. Coulter Foundation
Society for Laboratory Automation and Screening
Beckman Coulter Life Sciences
American Academy of Implant Dentistry Foundation (AAID/AAIDF)
National Medical Research Council, Singapore
National Research Foundation, Singapore